Summary of current therapeutic options for peritoneal metastases from colorectal cancer

Journal of Surgical Oncology

Volumn 107, Issue 6, 2013, Pages 566-573

  Chua, Terence C ^a,b   Esquivel, Jesus ^b   Pelz, Joerg O W ^c   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST AGNES HOSPITAL   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Bevacizumab; Cetuximab; colorectal cancer; fluorouracil; Irinotecan; metastasis; Oxaliplatin; peritoneal carcinomatosis; systemic chemotherapy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN;

CANCER CHEMOTHERAPY; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; HUMAN; OVERALL SURVIVAL; PALLIATIVE THERAPY; PERITONEUM METASTASIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; PALLIATIVE CARE; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; PERITONEUM; TREATMENT OUTCOME;

EID: 84876419545     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23189     Document Type: Review

References (56)

1. Koppe MJ, Boerman OC, Oyen WJG, et al.: Peritoneal carcinomatosis of colorectal origin: Incidence and current treatment strategies [see comment]. Ann Surg 2006; 243: 212-222.
2. Welch JP, Doanldson GA,: The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979; 189: 496-502.
3. Gilbert JM,: Distribution of metastases at necropsy in colorectal cancer. Clin Exp Metastasis 1983; 1: 97-101.
4. Weiss L, Grundmann E, Torhorst J, et al.: Haematogenous metastastic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol 1986; 150: 195-203.
5. Sugarbaker PH, Yu W, Yonemura Y,: Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: The evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 2003; 21: 233-248.
6. Paget S,: The distribution of secondary growths in cancer of the breast. Lancet 1889; 133: 571-573.
7. Hart IR, Fidler IJ,: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980; 40: 2281-2287.
8. Kawajiri H, Yashiro M, Shinto O, et al.: A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res 2008; 14: 2850-2860.
9. Furuya M, Kato H, Nishimura N, et al.: Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: Morphologic alteration and reduced expression of beta1 integrin subsets. Cancer Res 2005; 65: 2617-2625.
10. Takatsuki H, Komatsu S, Sano R, et al.: Adhesion of gastric carcinoma cells to peritoneum mediated by alpha3beta1 integrin (VLA-3). Cancer Res 2004; 64: 6065-6070.
11. Yonemura Y, Fujimura T, Ninomiya I, et al.: Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase- polymerase chain reaction for matrix metalloproteinase-7 mRNA. Clin Cancer Res 2001; 7: 1647-1653.
12. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group [see comment]. N Engl J Med 2000; 343: 905-914.
13. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [see comment]. N Engl J Med 2004; 350: 2335-2342.
14. Colucci G, Gebbia V, Paoletti G, et al.: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875.
15. Cassidy J, Clarke S, Diaz-Rubio E, et al.: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
16. Porschen R, Arkenau H-T, Kubicka S, et al.: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217-4223.
17. Saltz LB, Clarke S, Diaz-Rubio E, et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
18. Falcone A, Ricci S, Brunetti I, et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
19. Pfannschmidt J, Dienemann H, Hoffmann H,: Surgical resection of pulmonary metastases from colorectal cancer: A systematic review of published series. Ann Thorac Surg 2007; 84: 324-338.
20. Carpizo DR, D'Angelica M,: Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Lancet Oncol 2009; 10: 801-809.
21. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al.: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 4575-4580.
22. Verwaal VJ, Bruin S, Boot H, et al.: 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432.
23. Sugarbaker PH,: Peritonectomy procedures. Ann Surg 1995; 221: 29-42.
24. Bijelic L, Yan TD, Sugarbaker PH,: Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J Surg Oncol 2008; 98: 295-299.
25. Bloemendaal ALA, Verwaal VJ, van Ruth S, et al.: Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: A prospective study. Eur J Surg Oncol 2005; 31: 1145-1151.
26. Catalano V, Loupakis F, Graziano F, et al.: Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer 2009; 100: 881-887.
27. Chua TC, Yan TD, Ng KM, et al.: Significance of lymph node metastasis in patients with colorectal cancer peritoneal carcinomatosis. World J Surg 2009; 33: 1488-1494.
28. Elias D, Delperro JR, Sideris L, et al.: Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004; 11: 518-521.
29. Elias D, Lefevre JH, Chevalier J, et al.: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-685.
30. Franko J, Gusani NJ, Holtzman MP, et al.: Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer [see comment]. Ann Surg Oncol 2008; 15: 3065-3072.
31. Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004; 22: 3284-3292.
32. Hagendoorn J, van Lammeren G, Boerma D, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival. Eur J Surg Oncol 2009; 35: 833-837.
33. Hasegawa S, Mukai M, Sato S, et al.: Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination. Oncol Rep 2006; 15: 1185-1190.
34. Higashi H, Shida H, Ban K, et al.: Factors affecting successful palliative surgery for malignant bowel obstruction due to peritoneal dissemination from colorectal cancer. Jpn J Clin Oncol 2003; 33: 357-359.
35. Jayne DG, Fook S, Loi C, et al.: Peritoneal carcinomatosis from colorectal cancer [see comment]. Br J Surg 2002; 89: 1545-1550.
36. Kianmanesh R, Scaringi S, Sabate J-M, et al.: Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg 2007; 245: 597-603.
37. Kohne CH, Cunningham D, Di Costanzo F, et al.: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
38. Machida N, Yoshino T, Boku N, et al.: Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. Jpn J Clin Oncol 2008; 38: 689-694.
39. Sadeghi B, Arvieux C, Glehen O, et al.: Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-363.
40. Shen P, Thai K, Stewart JH, et al.: Peritoneal surface disease from colorectal cancer: Comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol 2008; 15: 3422-3432.
41. Verwaal VJ, van Ruth S, de Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer [see comment]. J Clin Oncol 2003; 21: 3737-3743.
42. Verwaal VJ, van Ruth S, Witkamp A, et al.: Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: 65-71.
43. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comment]. J Natl Cancer Inst 2000; 92: 205-216.
44. Sugarbaker PH,: Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: The Washington Cancer Institute approach. Expert Opin Pharmacother 2009; 10: 1965-1977.
45. Spratt JS, Adcock RA, Muskovin M, et al.: Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40: 256-260.
46. Elias D, Bonnay M, Puizillou JM, et al.: Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 2002; 13: 267-272.
47. Mahteme H, Larsson B, Sundin A, et al.: Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery. An autoradiographic study in the rat. Eur J Cancer 2004; 40: 142-147.
48. Cao C, Yan TD, Black D, et al.: A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2009; 16: 2152-2162.
49. Chua TC, Yan TD, Saxena A, et al.: Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality. Ann Surg 2009; 249: 900-907.
50. Moradi BN III, Esquivel J,: Learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2009; 100: 293-296.
51. Petrelli NJ, Abbruzzese J, Mansfield P, et al.: Hepatic resection: The last surgical frontier for colorectal cancer. J Clin Oncol 2005; 23: 4475-4477.
52. Khatri VP, Petrelli NJ, Belghiti J,: Extending the frontiers of surgical therapy for hepatic colorectal metastases: Is there a limit? J Clin Oncol 2005; 23: 8490-8499.
53. Kaido T,: Verification of evidence in surgical treatment for colorectal liver metastasis. Hepato-Gastroenterology 2008; 55: 378-380.
54. Cao CQ, Yan TD, Liauw W, et al.: Comparison of optimally resected hepatectomy and peritonectomy patients with colorectal cancer metastasis. J Surg Oncol 2009; 100: 529-533.
55. Gertsch P,: A historical perspective on colorectal liver metastases and peritoneal carcinomatosis: Similar results, different treatments. Surg Oncol Clin N Am 2003; 12: 531-541.
56. Varban O, Levine EA, Stewart JH, et al.: Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases. Cancer 2009; 115: 3427-3436.